Quantity | = | Concentration | x | Volume | x | Molecular Weight |
---|---|---|---|---|---|---|
= | x | x |
1) Click the Molarity Calculation Cart® button.
2) Specify the Concentration and Volume of your desired Molarity.
3) Click Calculate.
4) Your desired Quantity will be calculated and will be put under Quantity: (only for mg)
5) Click Add to Cart and then Proceed to checkout to complete the order. You will receive the quantity as you ordered as solvent-free form.
Alert: If you want to make a solution with a solvent (such DMSO), please add instructions in the notes section (such as 10 nM/1 mL in DMSO) and we will pack and deliver the product as a solution (such as 10 nM solution in 1 mL DMSO). If the product cannot be dissolved in DMSO or you would like to specify your own preferred solvent, please add detailed instructions in the notes section. All solutions must be shipped with an ice bag, costing an additional fee of $20 for S&H.
AOB13246
CAS: 1691249-45-2
Chemical Name: BGB-3111; (7S)-2-(4-Phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
Warning: Last items in stock!
Availability date:
Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
---|---|---|---|
1 | 100 | $22.05 | Total: $2,205.00 |
1 | 50 | $25.48 | Total: $1,274.00 |
1 | 25 | $29.89 | Total: $747.25 |
1 | 10 | $35.28 | Total: $352.80 |
1 | 5 | $41.65 | Total: $208.25 |
Molecular Formula | C27H29N5O3 |
Molecular Weight | 471.56 |
CAS Numbers | 1691249-45-2 (S-isomer) |
Storage Condition | 0°C (short term), -20°C (long term), desiccated |
Solubility | DMSO |
Purity | 98% by HPLC |
Synonym | BGB-3111; BGB 3111; BGB3111; Zanubrutinib; Brukinsa. |
IUPAC/Chemical Name | (7S)-4,5,6,7-Tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide |
InChl Key | RNOAOAWBMHREKO-QFIPXVFZSA-N |
InChl Code | InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1 |
SMILES Code | O=C(C1=C2NCC[C@@H](C3CCN(C(C=C)=O)CC3)N2N=C1C4=CC=C(OC5=CC=CC=C5)C=C4)N |
References | 1) Wong J, Cher L, Griffiths J, Cohen A, Huang J, Wang L, Gregory G, Opat S. Efficacy of Zanubrutinib in the Treatment of Bing-Neel Syndrome. Hemasphere. 2018 Nov 30;2(6):e155. doi: 10.1097/HS9.0000000000000155. eCollection 2018 Dec. PubMed PMID: 31723793; PubMed Central PMCID: PMC6745965. 2) Zou YX, Zhu HY, Li XT, Xia Y, Miao KR, Zhao SS, Wu YJ, Wang L, Xu W, Li JY. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Hematol Oncol. 2019 Oct;37(4):392-400. doi: 10.1002/hon.2667. Epub 2019 Sep 13. PubMed PMID: 31420873. |
Novel, Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK)